Jgi/jamie Grill | Tetra Images | Getty Images
A version of this text first appeared in CNBC’s Healthy Returns newsletter, which brings the most recent health-care news straight to your inbox. Subscribe here to receive future editions.
Tariff threats — and efforts to get into President Donald Trump’s good graces — are fueling a brand new wave of U.S. manufacturing investments from the pharmaceutical industry.
We’re here to bring you a roundup of those plans, that are exactly what the Trump administration desires to see at a time when domestic drug manufacturing has shrunk significantly.
There aren’t any latest updates on what Trump’s planned tariffs on pharmaceuticals imported into the uswill seem like or once they shall be announced.
But drugmakers are already bracing for those pharmaceutical-specific levies as they grapple with evolving trade policy, with many announcing latest investments within the U.S. to construct goodwill with the president.
Reshoring manufacturing may also help make the drug supply chain more robust, decreasing the chance of disruptions, in keeping with an April release from GlobalData, a knowledge and analytics company. Still, it could elevate production costs and drug prices, raising affordability concerns, GlobalData said.
Here’s an inventory of the businesses which have announced latest U.S. investments since Trump took office:
Other corporations, similar to GSK, also announced U.S. investments last 12 months.
Meanwhile, Pfizer CEO Albert Bourla on Tuesday said uncertainty around pharmaceutical tariffs is deterring the corporate from further investing in U.S. manufacturing and research and development.
“If I do know that there is not going to be tariffs … then there are tremendous investments that may occur on this country, each in R&D and manufacturing,” Bourla said on the decision, adding that the corporate can also be hoping for “certainty.”
Be at liberty to send any suggestions, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.
Latest in health-care tech: Abbott’s CGM data will integrate with Epic’s EHR
Abbott Laboratories on Tuesday announced that data from its Libre continuous glucose monitoring systems will integrate directly with Epic Systems’ electronic health record (EHR) software within the U.S.
A continuous glucose monitor, or a CGM, is a small sensor that pokes through the skin and sends real-time glucose readings to an app. Glucose is a sort of sugar people get from food, and it’s people’s principal energy source. Managing glucose is crucial for patients with diabetes to prevent and delay serious health problems, in keeping with the Centers for Disease Control and Prevention.
Abbott’s integration with Epic will allow doctors to view their patients’ glucose data before, during and after visits, and it’s meant to assist them access the data in an easy and actionable way. Abbott is working with Epic’s Aura software, which connects health systems with medical device manufacturers and diagnostics labs, in keeping with a release.
Abbott said there’s more to come back.
“While the combination with Libre data is Abbott’s first medical device offering with Epic, it’s only the start,” Lisa Earnhardt, executive vp of medical devices for Abbott, said in a release. “We aim to expand this model to our other medical devices and connected care platforms in the long run.”
Abbott sells a variety of CGM systems, and it is the market leader within the space based on variety of users, in keeping with a 2024 market model from the firm William Blair.
Dexcom, a competing CGM company, is the second largest player behind Abbott, in keeping with William Blair. Dexcom also offers its own direct EHR integration solution, which is offered to customers using Epic’s software.
An EHR is a digital version of a patient’s medical history that is updated by doctors and nurses. It’s crucial software inside the fashionable U.S. health-care system. Epic, the leading EHR vendor within the U.S., stores the medical records of greater than 280 million Americans.
“Diabetes requires close collaboration between patients, primary care providers, and specialists to administer a fancy and time-critical care plan,” Alan Hutchison, vp at Epic, said in the discharge. “It will help everyone focus more on patient care and fewer on administrative hurdles.”
Be at liberty to send any suggestions, suggestions, story ideas and data to Ashley at ashley.capoot@nbcuni.com.
